# Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis

> **NCT04943302** · PHASE2 · WITHDRAWN · sponsor: **Tufts Medical Center**

## Conditions studied

- Amyloidosis
- Light Chain (AL) Amyloidosis

## Interventions

- **DRUG:** Bendamustine Hydrochloride
- **DRUG:** Isatuximab

## Key facts

- **NCT ID:** NCT04943302
- **Lead sponsor:** Tufts Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-09-01
- **Primary completion:** 2024-09
- **Final completion:** 2026-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI left institution. Study not moving forward in her absence.
- **Last updated:** 2024-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04943302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04943302, "Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04943302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*